Atossa Therapeutics, Inc. ATOS

Company Overview

Atossa Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on the development of therapies for breast cancer and other breast conditions. The company operates within the biotechnology and oncology sectors, with research efforts centered on endocrine-responsive breast cancer, prevention strategies, and treatments designed to improve outcomes while potentially reducing toxicity associated with conventional therapies. Atossa’s primary value driver is its proprietary drug development pipeline, particularly oral formulations and endocrine-based therapeutic approaches targeting breast cancer patients in both early-stage and metastatic settings.

The company was founded in 2008 and is headquartered in Seattle, Washington. Earlier in its corporate history, Atossa pursued diagnostic technologies and breast health testing products, but it later shifted its strategy toward therapeutic drug development. Its current positioning is tied to differentiated endocrine therapy programs, including investigations involving selective estrogen receptor modulation and metabolism-based oncology treatments. Public filings and company disclosures indicate that Atossa’s evolution reflects a transition from diagnostics into a focused oncology therapeutics platform emphasizing breast cancer treatment innovation.